PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 20260 citationsOpen Access

Chemotherapy in Combination With Methionine Restriction Induced A Complete Response in a Patient With Recurrent Metastatic Tongue Squamous-Cell Carcinoma.

View Full Paper
TITomoyuki IshiguroTSTOSHIHIKO SATOQHQINGHONG HAN

Key Points

  • To explore the efficacy of chemotherapy combined with methionine restriction in recurrent head and neck squamous-cell carcinoma.
  • Documented case of a patient with recurrent tongue HNSCC receiving chemotherapy and methionine restriction.
  • Performed imaging studies including PET/CT and MRI to monitor tumor response.
  • Follow-up treatment involved cetuximab and continued methionine restriction.
  • Rapid tumor regression was observed post-treatment.
  • Follow-up imaging confirmed a complete response was achieved and maintained.
  • Treatment showed potential clinical efficacy after prior standard therapy failures.

Abstract

Background/Aim: Recurrent head and neck squamous-cell carcinoma (HNSCC) is associated with poor prognosis and limited treatment options, particularly after failure of standard therapies including surgery, radiotherapy, chemotherapy, and immune checkpoint inhibitors. Methionine restriction has emerged as a novel clinical metabolic therapeutic strategy targeting the methionine addiction of cancer cells. The present patient report describes a case of recurrent tongue HNSCC that achieved complete remission with chemotherapy combined with methionine restriction. Case Report: F]fluorodeoxyglucose positron-emission tomography (PET)/computed tomography (CT) performed according to standard clinical protocols. Rapid tumor regression was observed. Follow-up magnetic resonance imaging (MRI) and PET/CT demonstrated complete response, which was maintained after de-escalation to cetuximab combined with MR. Conclusion: The present case demonstrates the potential clinical efficacy of combining chemotherapy with MR in the treatment of recurrent HNSCC after curative-intent surgery and failure of standard therapies, including immune checkpoint inhibition. MR may represent a promising metabolic therapeutic approach for refractory HNSCC. Αdditional cases and prospective clinical trials are necessary.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ishiguro et al. (2026) studied this question.

synapsesocial.com/papers/69fada7f03f892aec9b1e504https://doi.org/10.21873/cdp.10542
Ask AI
Helpful
Bookmark
Share
View Full Paper